Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

Author:

Larkin James1,Chiarion-Sileni Vanna1,Gonzalez Rene1,Grob Jean-Jacques1,Rutkowski Piotr1,Lao Christopher D.1,Cowey C. Lance1,Schadendorf Dirk1,Wagstaff John1,Dummer Reinhard1,Ferrucci Pier F.1,Smylie Michael1,Hogg David1,Hill Andrew1,Márquez-Rodas Ivan1,Haanen John1,Guidoboni Massimo1,Maio Michele1,Schöffski Patrick1,Carlino Matteo S.1,Lebbé Céleste1,McArthur Grant1,Ascierto Paolo A.1,Daniels Gregory A.1,Long Georgina V.1ORCID,Bastholt Lars1,Rizzo Jasmine I.1,Balogh Agnes1,Moshyk Andriy1,Hodi F. Stephen1,Wolchok Jedd D.1

Affiliation:

1. From the Royal Marsden NHS Foundation Trust, London (J.L.), and the College of Medicine, Swansea University, Swansea (J.W.) — both in the United Kingdom; the Oncology Institute of Veneto IRCCS, Padua (V.C.-S.), the European Institute of Oncology, IRCCS, Milan (P.F.F.), Istituto Nazionale Tumori IRCCS Fondazione Pascale, Naples (P.A.A.), the Immunotherapy and Somatic Cell Therapy Unit, IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola (M.G.), and the Center for Immuno...

Publisher

Massachusetts Medical Society

Subject

General Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3